ClinicalTrials.gg
CompletedNCT02176005Updated Feb 28, 2020Results posted

Safety and Efficacy Study of DAV132 in Healthy Volunteers

A Phase 1 interventional study of DAV132 and Moxifloxacin in Healthy, sponsored by Da Volterra. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-28.

Sponsored by Da Volterra · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether DAV132 is safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.

Read the detailed description

The proposed study, DAV132-CL-1002, is to evaluate performances of DAV132 in healthy volunteers:

  • To capture residual concentration of antibiotics in colon without interfering with their systemic pharmacokinetics parameters.
  • To explore the influence of DAV132 to prevent the modification of gut flora due to antibiotic.

In addition, the security and acceptability of DAV132 used during 7 days will be evaluated.

The proposed study is prospective, randomized, controlled, four parallel groups, repeated doses, open-label study blinded to analytical and microbiological evaluations.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Da Volterra is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • Normal digestive transit, with usually one daily stool.
  • Females participating in the study :

must be either of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or or having a negative pregnancy test and be not breastfeeding at screening, and using abstinence or a double method during the treatment period and for additional period of 2 weeks after the end of treatment.

  • Having given and signed the written study prior to undertaking any study-related procedure.
  • Covered by the French Health Insurance system.

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, bone and joint, muscular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness.
  • to fluoroquinolones, or risk factors for adverse events associated to fluoroquinolones.
  • Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency should be excluded.
  • Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be excluded.
  • Contra-indications to DAV132, risk of gastrointestinal obstruction, perforation or haemorrhage, recent digestive tract surgery.
  • Fecal colonisation by Clostridium difficile.
  • Recent history of hospitalisation (within 3 months prior to inclusion).
  • Any antibiotic administration within 3 months before inclusion.
  • Any vaccination within the last 28 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Moxifloxacin

    Moxifloxacin, oral tablets, 400mg/day, once daily 5 days

    Drug: Moxifloxacin

  • Experimental
    moxifloxacin + DAV132

    Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days

    Device: DAV132 · Drug: Moxifloxacin

  • Experimental
    DAV132

    DAV132 oral, 7.5g x3/day for 7 days

    Device: DAV132

  • Placebo comparator
    Negative control

    Negative control: 7.5g x3/day for 7 days

    Other: Negative Control

Interventions

  • DeviceDAV132

    DAV132 is associated to moxifloxacin or it is evaluated alone

  • Moxifloxacin is used alone or associated to DAV132

    Also known as: Avelox

  • OtherNegative Control

    Moxifloxacin is used alone

06

What researchers measure

Primary outcomes

  1. Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)

    Time frame: D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16

Secondary outcomes

  1. Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)

    Time frame: D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16, D23, D30, D37

  2. Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1

    Time frame: D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose

  3. Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5

    Time frame: D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose

  4. Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1

    Time frame: D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose

  5. Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5

    Time frame: D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose

  6. Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product

    Time frame: From randomization to 37 days after the beginning of treatment

  7. Percentage of Subjects With Adverse Events Related to Study Product

    Time frame: From randomization to 37 days after the beginning of treatment

07

Results

Posted Feb 28, 2020

Participant flow

Healthy volunteers were recruited from March 20th, 2014 (date of first enrolment) and October 17th, 2014 (date of last completed)

Participant flow — Overall Study
MilestoneMoxifloxacinDAV132 + MoxifloxacinDAV132Negative Control
Started141488
Completed141488
Not completed0000

Outcome measures

PrimaryMoxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)
Time frame:
D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16
Reported as:
Mean · μg/g.day
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)
μg/g.dayMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)758.4 ± 359.38.28 ± 7.21
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = <.000001 · Contrast (b/a): 0.0093 · 95% CI 0.0060 to 0.0144
SecondaryMoxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)
Time frame:
D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16, D23, D30, D37
Reported as:
Mean · μg/g.day
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)
μg/g.dayMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)758.7 ± 359.58.74 ± 7.73
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = <.000001 · Contrast (b/a): 0.0096 · 95% CI 0.0061 to 0.0151
SecondaryMoxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1
Time frame:
D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose
Reported as:
Mean · µg/mL.h
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1
µg/mL.hMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D142.1 ± 7.0141.9 ± 9.57
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = 0.806 · Contrast (b/a): 0.9811 · 95% CI 0.8608 to 1.1182
SecondaryMoxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5
Time frame:
D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose
Reported as:
Mean · µg/mL.h
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5
µg/mL.hMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D557.6 ± 13.8350.5 ± 10.91
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = 0.139 · Contrast (b/a): 0.8785 · 95% CI 0.7600 to 1.0155
SecondaryMoxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1
Time frame:
D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose
Reported as:
Mean · µg/mL
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1
µg/mLMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D14.02 ± 1.334.63 ± 0.97
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = 0.104 · Contrast (b/a): 1.1763 · 95% CI 0.9982 to 1.3861
SecondaryMoxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5
Time frame:
D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose
Reported as:
Mean · µg/mL
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5
µg/mLMoxifloxacinMoxifloxacin + DAV132
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D54.89 ± 1.214.60 ± 1.24
Statistical analysis
  • Moxifloxacin vs Moxifloxacin + DAV132 · General linear model · p = 0.519 · Contrast (b/a): 0.9391 · 95% CI 0.7969 to 1.1066
SecondaryNumber of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product
Time frame:
From randomization to 37 days after the beginning of treatment
Reported as:
Number · events related to study product
Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product
events related to study productMoxifloxacinMoxifloxacin + DAV132DAV132Negative Control
Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product1000
SecondaryPercentage of Subjects With Adverse Events Related to Study Product
Time frame:
From randomization to 37 days after the beginning of treatment
Reported as:
Number · % of subjects with at last 1 related AE
Percentage of Subjects With Adverse Events Related to Study Product
% of subjects with at last 1 related AEMoxifloxacinMoxifloxacin + DAV132DAV132Negative Control
Percentage of Subjects With Adverse Events Related to Study Product7.14000

Adverse events

Collected over Treatment period: - 5 days for Moxifloxacin group; - 7 days for the 3 other groups (DAV132 + Moxifloxacin, DAV132 and Negative Control groups). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin0/14 (0%)0/14 (0%)6/14 (42.9%)
Moxifloxacin + DAV1320/14 (0%)0/14 (0%)10/14 (71.4%)
DAV1320/8 (0%)0/8 (0%)2/8 (25%)
Negative Control0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMoxifloxacinMoxifloxacin + DAV132DAV132Negative Control
HeadacheNervous system disorders1/144/141/80/8
FlatulenceGastrointestinal disorders0/142/140/80/8
DiarrhoeaGastrointestinal disorders0/140/140/81/8
Intestinal transit time abnormalInvestigations0/140/141/80/8
DysmenorrhoeaReproductive system and breast disorders0/140/141/80/8
Abdominal painGastrointestinal disorders1/141/140/80/8
NauseaGastrointestinal disorders1/140/140/80/8
AstheniaGeneral disorders1/141/140/80/8
Ligament sprainInjury, poisoning and procedural complications0/141/140/80/8
ArthralgiaMusculoskeletal and connective tissue disorders0/141/140/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)MoxifloxacinDAV132 + MoxifloxacinDAV132Negative ControlTotal
Mean35.4 ± 10.438.6 ± 12.127.9 ± 9.136.7 ± 11.835.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)MoxifloxacinDAV132 + MoxifloxacinDAV132Negative ControlTotal
Female9104528
Male544316
Region of Enrollment
Region of Enrollment(Participants)MoxifloxacinDAV132 + MoxifloxacinDAV132Negative ControlTotal
France14148844
Body Mass Index (BMI) at screening visit
Body Mass Index (BMI) at screening visit(kg/m^2)MoxifloxacinDAV132 + MoxifloxacinDAV132Negative ControlTotal
Mean24.1 ± 3.324.9 ± 3.223.6 ± 3.223.3 ± 2.024.1 ± 3.0
08

Study locations

1 site
  • CLINICAL INVESTIGATION CENTER (CIC), Groupe Hospitalier Bichat-Claude Bernard
    Paris, 75O18, France
09

References and documents

Publications

  • Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis. 2000;32(1):81-5. doi: 10.1080/00365540050164272. PubMed 10716083 ↗
  • Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, Lode H. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34(12):898-903. doi: 10.1080/0036554021000026963. PubMed 12587622 ↗
  • de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppe E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentre F, Andremont A. Protection of the Human Gut Microbiome From Antibiotics. J Infect Dis. 2018 Jan 30;217(4):628-636. doi: 10.1093/infdis/jix604. PubMed 29186529 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 26, 2014
Start
Mar 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Results first posted
Feb 28, 2020
Last update
Feb 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02176005
Lead sponsor
Da Volterra
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Mar 2014
Primary completion
Oct 2014
Completion
Dec 2014
Results posted
Feb 28, 2020
Last update
Feb 28, 2020

Study contacts

Xavier Duval, MD
principal investigator · CIC Bichat, Paris France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion